Author

N. Schneiderhan-Marra

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Assay:proteomics· 4 Research Focus:cell type annotation· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

B. Traenkle· 3 shared P. D. Kaiser· 3 shared T. R. Wagner· 3 shared U. Rothbauer· 3 shared A. Dulovic· 2 shared A. Scholz· 2 shared A. Zeck· 2 shared D. Junker· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

B. Traenkle

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Development and validation of a respiratory syncytial virus multiplex immunoassay

P. Marsall, M. Fandrich, J. Griesbaum, M. Harries, B. Lange, RESPINOW study consortium, S. Ascough, P. Dayananda, C. Chiu, J. Remppis, T. Ganzenmueller, H. Renk, M. Strengert, N. Schneiderhan-Marra, A. Dulovic

The paper develops and validates a multiplex immunoassay for RSV antibodies, showing robust performance and subtype identification capability.

Infection · Feb 8, 2024Peer-reviewedImmunology

A broadly neutralizing biparatopic Nanobody protects mice from lethal challenge with SARS-CoV-2 variants of concern

T. R. Wagner, D. Schnepf, J. Beer, K. Klingel, N. Ruetalo, P. D. Kaiser, D. Junker, M. Sauter, B. Traenkle, D. I. Frecot, M. Becker, N. Schneiderhan-Marra, A. Ohnemus, M. Schwemmle, M. Schindler, U. Rothbauer

This study identifies a biparatopic nanobody that protects mice from lethal SARS-CoV-2 infection and reduces viral load and inflammation.

bioRxiv · Aug 8, 2021 · PreprintBiochemistry

Single-domain antibodies for targeting, detection and in vivo imaging of human CD4+ cells

B. Traenkle, P. D. Kaiser, S. Pezzana, J. Richardson, M. Gramlich, T. R. Wagner, D. Seyfried, M. Weldle, S. Holz, Y. Parfyonova, M. Schaller, S. Nueske, A. Scholz, A. Zeck, M. Jakobi, , U. Rothbauer

This study develops single-domain antibodies to target and image human CD4+ cells in vivo, demonstrating their utility in immunotherapy monitoring.

bioRxiv · Jul 2, 2021Immunology

NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response

T. R. Wagner, P. D. Kaiser, M. Gramlich, E. Ostertag, N. Ruetalo, D. Junker, J. Haering, B. Traenkle, M. Becker, A. Dulovic, H. Schweizer, S. Nueske, A. Scholz, A. Zeck, K. Schenke-Layland, , U. Rothbauer

The paper develops NeutrobodyPlex, a multiplex assay using bivalent nanobodies to analyze neutralizing antibodies against SARS-CoV-2 in patient sera.

bioRxiv · Sep 22, 2020 · PreprintImmunology

Neutrophil-extracellular trap-associated RNA (naRNA) and LL37 enable self-amplifying inflammation in psoriasis

F. Herster, Z. Bittner, S. Dickhoefer, D. Eisel, T. Eigenbrod, T. Knorpp, N. Schneiderhan-Marra, M. W. Loeffler, H. Kalbacher, D. Hartl, L. Freund, K. Schaekel, M. Heiser, K. Ghoreschi, A. N. R. Weber

The paper shows RNA-LL37 complexes activate neutrophils via TLR8, leading to cytokine release and NET formation, which may drive self-sustaining inflammation in psoriasis.

bioRxiv · Feb 19, 2019 · PreprintImmunology